CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 99 enrolled
Drug / intervention
Light Therapy +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02582398
NCT02582398N/ACompleted
CompareCT.gov

Influence of Light Exposure on Cerebral Monoamine Oxidase A in Seasonal Affective Disorder and Healthy Controls Measured by PET

Medical University of Vienna·interventional·Posted Oct 21, 2015·Updated May 9, 2018

In Brief

A clinical study evaluating Light Therapy and Placebo Light for Seasonal Affective Disorder. Completed, enrolled 99 participants across 1 site.

Detailed Summary

This study aims to assess differences in monoamine oxidase A (MAO-A) distribution in the brain between seasonal affective disorder patients and healthy controls using positron emission tomography. In addition the investigators aim to demonstrate the impact of light therapy on MAO-A distribution In addition, a pilot study and a sub-study in healthy controls were performed

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Affective Disorder
CountriesAustria
Collaborators--

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedOct 21, 2015
Enrollment StartNov 1, 2013
Primary CompletionApr 3, 2017
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 10.7 years ago

Interventions

Light Therapyother

One subgroup of SAD patients and healthy controls respectively will receive bright light therapy using an artificial white light source (PhysioLight LD220 by DAVITA®, www.davita.de/shop/lichttherapiegeraete/lichtduschen-tageslicht/physiolight-ld-220.html) with full-spectrum 10.000lux light intensity. The treatment will be applied 30min per day at a distance of about of 50cm, preferably in the morning, during 3 weeks.

Placebo Lightother

The second subgroup of the SAD patients and healthy controls will receive a non-biologically active light source (\<400nm or \>500nm). Here, the lamp will have largely similar shape and size as compared to the therapeutic device, but the fluorescent tube with the high light intensity will be replaced by an ordinary bulb.